1. In Vivo

Immuno-Oncology Is Making Pharma Step Up Its Diagnostics Game

 
• By Alex Vadas

Immuno-oncology has significant diagnostic needs including identifying patients most likely to respond to therapies. Current diagnostic approaches often fall short, due in large part to the complexity of the biology driving therapy responsiveness. As such, the biopharma industry is exploring many emerging approaches covering tumor, immune and even microbiome-related pathways and biomarkers.

IV1802_LEK_1200x675.jpg

Immuno-oncology represents a paradigm shift in cancer treatment, with the first wave of PD-1/PD-L1 checkpoint inhibitors such asOpdivo (nivolumab, from Bristol-Myers Squibb Co.) and Keytruda (Merck & Co. Inc.’s pembrolizumab) demonstrating cure-like performance in selected metastatic tumors such as non-small cell lung cancer (NSCLC) and melanoma.

This efficacy is driving significant checkpoint inhibitor adoption, and analysts project the class alone could represent a $29 billion global...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By David Wild

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.